Valsartan inhibits transient receptor potential canonical-3 channel in canine atrial fibrillation

Int J Cardiol. 2013 Oct 9;168(4):4417-8. doi: 10.1016/j.ijcard.2013.05.029. Epub 2013 May 25.

Authors

Jing Zhao¹, Xiaoyu Wang, Pengzhou Hang, Fengxiang Yun, Hongwei Zhao, Wei Xu, Danghui Sun, Li Sun, Yue Li

Affiliation

¹ Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang Province, China; Key Laboratory of Cardiac Diseases and Heart Failure, Harbin Medical University, Harbin 150001, Heilongjiang Province, China.

PMID: 23711449
DOI: 10.1016/j.ijcard.2013.05.029

No abstract available

Keywords: Atrial fibrillation; Transient receptor potential canonical-3; Valsartan; Western blotting.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin II Type 1 Receptor Blockers / pharmacology*
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Animals
Atrial Fibrillation / drug therapy*
Disease Models, Animal
Dogs
TRPC Cation Channels / antagonists & inhibitors*
Tetrazoles / pharmacology*
Tetrazoles / therapeutic use*
Valine / analogs & derivatives*
Valine / pharmacology
Valine / therapeutic use
Valsartan

Substances

Angiotensin II Type 1 Receptor Blockers
TRPC Cation Channels
TRPC3 cation channel
Tetrazoles
Valsartan
Valine